MindMaze Therapeutics Holding (XSWX:MMTX) Deferred Tax: CHF0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.18
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Deferred Tax?

MindMaze Therapeutics Holding XSWX:MMTX +3.33% 4 Deferred Tax is CHF0.00 Mil as of Dec. 2025. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review.

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

MindMaze Therapeutics Holding's change in deferred tax for the six months ended in Dec. 2025 was CHF0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.00 Mil.

MindMaze Therapeutics Holding Deferred Tax Related Terms

MindMaze Therapeutics Holding Deferred Tax Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Deferred Tax Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Deferred Tax
0.00 0.00

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Deferred Tax 0.00 0.00
XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
Deferred Tax is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Deferred Tax →
What does a Deferred Tax of CHF0.00 Mil mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Deferred Tax of CHF0.00 Mil as of Dec. 2025. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for MindMaze Therapeutics Holding.
Is MindMaze Therapeutics Holding's Deferred Tax too high?
MindMaze Therapeutics Holding's current Deferred Tax is CHF0.00 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Deferred Tax compare to VRTX and REGN?
MindMaze Therapeutics Holding's Deferred Tax of CHF0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Deferred Tax for a Biotechnology company?
A good Deferred Tax depends on the Biotechnology industry context. However, Deferred Tax should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Deferred Tax mean?
A high Deferred Tax can signal that a stock is expensive relative to its fundamentals. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for MindMaze Therapeutics Holding. MindMaze Therapeutics Holding's current Deferred Tax is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Deferred Tax of CHF0.00 Mil. The current Deferred Tax is CHF0.00 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Deferred Tax calculated?
Deferred Tax is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Deferred Tax is CHF0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

Deferred Tax is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.18
Price